Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Active not recruiting 5Completed 4Withdrawn 2Terminated 2Recruiting 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Ovarian Neoplasms 8Breast Neoplasms 6Prostatic Neoplasms 5Triple Negative Breast Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Small Cell Lung Carcinoma 2Prostatic Neoplasms, Castration-Resistant 2Lung Neoplasms 2Glioma 2Glioblastoma 2Uterine Cervical Neoplasms 1Solid Tumor 1Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasm, Residual 1Metastatic Castration-sensitive Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Neuroendocrine 1

Interventions

enzalutamide 33Abiraterone Acetate 29apalutamide 26Prednisone 26Radiotherapy 25Magnetic Resonance Spectroscopy 25Androgen Antagonists 24Leuprolide 22Radiosurgery 19darolutamide 18Docetaxel 17Gonadotropin-Releasing Hormone 16acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Goserelin 13gallium 68 PSMA-11 12bicalutamide 12Specimen Handling 12Radiotherapy, Intensity-Modulated 12abiraterone 11Radiation 11pembrolizumab 10Pluvicto 10Carboplatin 9Brachytherapy 92-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 9relugolix 8luprolide acetate gel depot 8Triptorelin Pamoate 8Standard of Care 8Nivolumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Prostatic Neoplasms × niraparib × Clear all
NCT05689021 2026-05-11

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Mayo Clinic

Phase 2 Active not recruiting
8 enrolled
Genitourinary

Prostatic Neoplasms

NCT04577833 2026-05-08

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Active not recruiting
136 enrolled
Genitourinary

Prostatic Neoplasms

NCT06212583 2026-05-06

KNIGHTS

University of Maryland, Baltimore

Phase 2 Active not recruiting
88 enrolled
Genitourinary

Prostatic Neoplasms

NCT04194554 2026-05-01

ASCLEPIuS

University of Michigan Rogel Cancer Center

Phase 1/2 Active not recruiting
102 enrolled
Genitourinary

Prostatic Neoplasms

NCT04592237 2025-12-23

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
120 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡